Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Companies	$5.41 -0.6%	$6.21	$3.96 ▼ $9.85	$2.00B	0.43	2.69 million shs	1.64 million shs
BLTE Belite Bio	$60.18 +3.3%	$61.09	$38.80 ▼ $86.53	$1.92B	-1.52	50,260 shs	37,274 shs
KYMR Kymera Therapeutics	$33.61 +1.1%	$29.80	$19.45 ▼ $53.27	$2.18B	2.22	554,166 shs	608,827 shs
URGN UroGen Pharma	$11.26 +14.1%	$10.44	$8.94 ▼ $20.70	$519.02M	0.8	524,564 shs	2.32 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Companies	-0.18%	+14.62%	-16.58%	-28.77%	-37.89%
BLTE Belite Bio	+3.35%	+10.04%	-9.78%	+1.76%	+51.40%
KYMR Kymera Therapeutics	+1.05%	+23.75%	+13.47%	-17.32%	+0.72%
URGN UroGen Pharma	+14.08%	+16.56%	+0.54%	+4.84%	-20.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Companies	4.1886 of 5 stars	2.9	3.0	4.0	2.6	1.7	1.9
BLTE Belite Bio	2.9163 of 5 stars	3.5	5.0	0.0	2.7	0.8	0.6
KYMR Kymera Therapeutics	1.8045 of 5 stars	3.4	2.0	0.0	2.1	1.7	0.0
URGN UroGen Pharma	4.3847 of 5 stars	4.5	2.0	4.5	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Companies	1.86	Reduce	$7.17	32.47% Upside
BLTE Belite Bio	3.00	Buy	$96.67	60.63% Upside
KYMR Kymera Therapeutics	2.87	Moderate Buy	$56.36	67.68% Upside
URGN UroGen Pharma	3.00	Buy	$32.86	191.80% Upside

Current Analyst Ratings Breakdown

Latest URGN, KYMR, BLTE, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/28/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/28/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
4/17/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$22.00 ➝ $16.00
4/16/2025	URGN UroGen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$23.00
4/7/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform	$9.00 ➝ $8.50
3/26/2025	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/18/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/18/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
3/13/2025	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$52.00
3/11/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $55.00
3/10/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Companies	$9.63B	0.21	$5.76 per share	0.94	($0.89) per share	-6.08
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
KYMR Kymera Therapeutics	$47.07M	46.37	N/A	N/A	$7.12 per share	4.72
URGN UroGen Pharma	$90.40M	5.74	N/A	N/A	($2.78) per share	-4.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Companies	-$46M	-$0.12	N/A	1.16	0.37	-0.48%	-577.82%	5.24%	4/30/2025 (Estimated)
BLTE Belite Bio	-$31.63M	-$1.18	N/A	N/A	N/A	N/A	-31.94%	-30.73%	5/12/2025 (Estimated)
KYMR Kymera Therapeutics	-$146.96M	-$2.97	N/A	N/A	N/A	-191.26%	-24.96%	-20.27%	5/1/2025 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.23	N/A	N/A	N/A	-129.11%	N/A	-47.94%	5/12/2025 (Estimated)

Latest URGN, KYMR, BLTE, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BLTE Belite Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	N/A	N/A	N/A	$22.71 million	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.93	N/A	N/A	N/A	$11.38 million	N/A
4/30/2025	Q1 2025	BHC Bausch Health Companies	$1.46	N/A	N/A	N/A	$2.29 billion	N/A
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million
2/27/2025	Q4 2024	KYMR Kymera Therapeutics	-$0.76	-$0.88	-$0.12	-$0.88	$14.81 million	$7.39 million
2/19/2025	Q4 2024	BHC Bausch Health Companies	$1.65	$1.21	-$0.44	$0.25	$2.51 billion	$2.56 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Companies	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Companies	N/A	0.86	0.62
BLTE Belite Bio	N/A	30.73	30.73
KYMR Kymera Therapeutics	N/A	8.55	8.55
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Companies	78.65%
BLTE Belite Bio	0.53%
KYMR Kymera Therapeutics	N/A
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Companies	8.12%
BLTE Belite Bio	13.29%
KYMR Kymera Therapeutics	15.82%
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Companies	19,900	369.51 million	338.06 million	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
KYMR Kymera Therapeutics	170	64.94 million	54.52 million	Optionable
URGN UroGen Pharma	200	46.09 million	22.26 million	Optionable

URGN, KYMR, BLTE, and BHC Headlines

Recent News About These Companies

UroGen Pharma announces results from Phase 1 study of UGN-301

April 28 at 11:59 AM | markets.businessinsider.com

Adage Capital Partners GP L.L.C. Has $31.18 Million Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

April 28 at 5:37 AM | marketbeat.com

UroGen Pharma announces long-term follow up data from OPTIMA II Phase 2b study

April 28 at 1:54 AM | markets.businessinsider.com

UroGen Pharma reports long-term follow-up study with JELMYTO

April 28 at 1:54 AM | markets.businessinsider.com

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

April 27 at 5:05 PM | businesswire.com

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

April 27 at 1:00 PM | businesswire.com

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

April 27 at 12:30 PM | businesswire.com

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

April 26 at 6:30 PM | businesswire.com

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

April 26 at 10:00 AM | businesswire.com

Silverarc Capital Management LLC Buys 219,344 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

April 24, 2025 | marketbeat.com

50,000 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Diadema Partners LP

April 24, 2025 | marketbeat.com

The Goldman Sachs Group Issues Pessimistic Forecast for UroGen Pharma (NASDAQ:URGN) Stock Price

April 20, 2025 | americanbankingnews.com

Alliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

April 19, 2025 | marketbeat.com

Scotiabank Initiates Coverage on UroGen Pharma (NASDAQ:URGN)

April 18, 2025 | marketbeat.com

Analysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Ligand Pharma (LGND)

April 17, 2025 | markets.businessinsider.com

UroGen Pharma initiated with an Outperform at Scotiabank

April 17, 2025 | markets.businessinsider.com

Scotiabank Initiates Coverage of UroGen Pharma (URGN) with Sector Outperform Recommendation

April 17, 2025 | msn.com

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

April 16, 2025 | benzinga.com

ExodusPoint Capital Management LP Acquires New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)

April 15, 2025 | marketbeat.com

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy

April 12, 2025 | seekingalpha.com

UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts

April 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, KYMR, BLTE, and BHC Company Descriptions

Bausch Health Companies NYSE:BHC

$5.41 -0.03 (-0.55%)

Closing price 04/28/2025 03:59 PM Eastern

Extended Trading

$5.38 -0.03 (-0.63%)

As of 04:26 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Belite Bio NASDAQ:BLTE

$60.18 +1.95 (+3.35%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$59.22 -0.96 (-1.59%)

As of 04:23 AM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Kymera Therapeutics NASDAQ:KYMR

$33.61 +0.35 (+1.05%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$33.61 0.00 (0.00%)

As of 04:21 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

UroGen Pharma NASDAQ:URGN

$11.26 +1.39 (+14.08%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$11.56 +0.30 (+2.62%)

As of 04:33 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time